相似文献
1
Rosuvastatin in patients with elevated C-reactive protein.
N Engl J Med. 2009 Mar 5;360(10):1041; author reply 1041-2.
2
Rosuvastatin in patients with elevated C-reactive protein.
N Engl J Med. 2009 Mar 5;360(10):1039; author reply 1041-2.
3
Rosuvastatin in patients with elevated C-reactive protein.
N Engl J Med. 2009 Mar 5;360(10):1039; author reply 1041-2.
4
Rosuvastatin in patients with elevated C-reactive protein.
N Engl J Med. 2009 Mar 5;360(10):1040; author reply 1041-2.
5
Rosuvastatin in patients with elevated C-reactive protein.
N Engl J Med. 2009 Mar 5;360(10):1038; author reply 1041-2. doi: 10.1056/NEJMc082574.
6
[Less vascular risk with rosuvastatin in elevated CRP].
Ned Tijdschr Geneeskd. 2009 Feb 7;153(6):245.
7
JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
Cardiovasc J Afr. 2009 May-Jun;20(3):211.
8
[JUPITER no support of changed guidelines for cardiovascular prevention. Moderate absolute risk reduction and uncertain long term effects].
Lakartidningen. 2009;106(21-22):1460-1.
9
[JUPITER study (2). For now no reason to give statins to more people].
Ned Tijdschr Geneeskd. 2009 Feb 7;153(6):218-9.
10
[JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
Ned Tijdschr Geneeskd. 2009 Feb 7;153(6):216-7.
引用本文的文献
1
Statins in primary prevention: is the enthusiasm justified?
Indian Heart J. 2020 Jul-Aug;72(4):221-224. doi: 10.1016/j.ihj.2020.07.021. Epub 2020 Aug 7.
2
Competing risks and the clinical community: irrelevance or ignorance?
Stat Med. 2012 May 20;31(11-12):1089-97. doi: 10.1002/sim.4384. Epub 2011 Sep 23.
Zotero 插件